DOASENSE - Home - Pioneering Point-of-Care Testing for DOACs

Go to content
Pioneering Novel Approaches to Testing for DOACs
 NEWS FLASH:
    • 2019-01: Meet us at these upcoming 2019 conferences:

    • 2018-11:   The DOAC Dipstick point-of-care test is now commercially available in Germany through HITADO [ORDER HERE] / Der DOAC Dipstick Point-of-Care-Test ist nun in Deutschland über HITADO erhältlich [BESTELLEN SIE HIER]

More News [HERE]
When every minute counts … fast DOAC testing matters.

DOASENSE’s mission objective is changing the landscape of testing for DOACs (new synthetic oral anticoagulants) with novel and quick point-of-care urine tests

The determination of DOACs has long been limited to blood sampling approaches, with all their potential limitations, and a rapid assessment of the anticoagulant effect of non-vitamin K antagonist oral anticoagulants (Direct Oral AntiCoagulants – DOACs) by point-of-care testing (POCT) so far has been an unmet clinical need.


DOASENSE develops products for specific testing for DOACs in urine

Tests which are easy to use and easy to interpret, reproducible, and patient friendly

Listen to what opinion leaders think about DOASENSE's solutions:
Typical clinical scenarios where testing for specific DOACs can be of value

    • Stroke (e.g. before thrombolytic therapy)
    • Trauma
    • Emergency procedures
    • Evaluating for venous thromboembolism
    • Spontaneous hemorrhage
    • General surgery or invasive procedures
    • Other situations where medication history may not available

In each of these situations the objective is establishing the absence of DOACs in the patient prior to procedure
Divider
NOTE: DOASENSE(TM) products may not be available or approved in your country.


Copyright (c) 2016-2019 DOASENSE GmbH. All rights reserved.
Back to content